105 related articles for article (PubMed ID: 28092730)
1. Serum AGR2 as a useful biomarker for pituitary adenomas.
Tohti M; Li J; Tang C; Wen G; Abdujilil A; Yizim P; Ma C
Clin Neurol Neurosurg; 2017 Mar; 154():19-22. PubMed ID: 28092730
[TBL] [Abstract][Full Text] [Related]
2. Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma.
Yu S; Wang XS; Cao KC; Bao XJ; Yu J
Chin Med Sci J; 2019 Sep; 34(3):168-176. PubMed ID: 31601299
[TBL] [Abstract][Full Text] [Related]
3. Serum AGR2 as an early diagnostic and postoperative prognostic biomarker of human lung adenocarcinoma.
Chung K; Nishiyama N; Yamano S; Komatsu H; Hanada S; Wei M; Wanibuchi H; Suehiro S; Kakehashi A
Cancer Biomark; 2011-2012; 10(2):101-7. PubMed ID: 22430137
[TBL] [Abstract][Full Text] [Related]
4. Expression of AGR2 in pituitary adenomas and its association with tumor aggressiveness.
Tohti M; Li J; Ma C; Li W; Lu Z; Hu Y
Oncol Lett; 2015 Nov; 10(5):2878-2882. PubMed ID: 26722256
[TBL] [Abstract][Full Text] [Related]
5. Elevated soluble epidermal growth factor receptor level in pituitary adenoma and carcinoma.
Kong YG; Ren ZY; Su CB; Wang RZ; Ma WB; Lian W
Chin Med Sci J; 2004 Sep; 19(3):199-202. PubMed ID: 15506648
[TBL] [Abstract][Full Text] [Related]
6. AGR2 diagnostic value in nasopharyngeal carcinoma prognosis.
Li Y; Wang W; Liu Z; Jiang Y; Lu J; Xie H; Tang F
Clin Chim Acta; 2018 Sep; 484():323-327. PubMed ID: 29269202
[TBL] [Abstract][Full Text] [Related]
7. [Measurement of soluble CD44v6 in peripheral blood as assistant diagnosis of invasive pituitary adenomas].
Kong YG; Su CB; Ren ZY; Wang RZ; Li GL; Dou WC; Zhang B; Tian SQ
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Dec; 25(6):698-701. PubMed ID: 14714315
[TBL] [Abstract][Full Text] [Related]
8. Serum alpha-subunit levels in patients with pituitary adenomas.
Samejima N; Yamada S; Takada K; Sano T; Ozawa Y; Shimizu T; Usui M; Shishiba Y
Clin Endocrinol (Oxf); 2001 Apr; 54(4):479-84. PubMed ID: 11318783
[TBL] [Abstract][Full Text] [Related]
9. Association of Ki-67 Labelling Index and IL-17A with Pituitary Adenoma.
Glebauskiene B; Liutkeviciene R; Vilkeviciute A; Gudinaviciene I; Rocyte A; Simonaviciute D; Mazetyte R; Kriauciuniene L; Zaliuniene D
Biomed Res Int; 2018; 2018():7490585. PubMed ID: 29955610
[TBL] [Abstract][Full Text] [Related]
10. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.
Kani K; Malihi PD; Jiang Y; Wang H; Wang Y; Ruderman DL; Agus DB; Mallick P; Gross ME
Prostate; 2013 Feb; 73(3):306-15. PubMed ID: 22911164
[TBL] [Abstract][Full Text] [Related]
11. Expression and clinical significance of doublecortin (DCX) in pituitary adenoma.
Liu X; Ma L; Wang Z; Ye J; Liu X; Jiang G; Wang H
Bull Cancer; 2019 Dec; 106(12):1080-1085. PubMed ID: 31376915
[TBL] [Abstract][Full Text] [Related]
12. Serum Cyr61 as a potential biomarker for diagnosis of colorectal cancer.
Song YF; Xu ZB; Zhu XJ; Tao X; Liu JL; Gao FL; Wu CL; Song B; Lin Q
Clin Transl Oncol; 2017 Apr; 19(4):519-524. PubMed ID: 27743169
[TBL] [Abstract][Full Text] [Related]
13. AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection.
Garczyk S; von Stillfried S; Antonopoulos W; Hartmann A; Schrauder MG; Fasching PA; Anzeneder T; Tannapfel A; Ergönenc Y; Knüchel R; Rose M; Dahl E
PLoS One; 2015; 10(4):e0122106. PubMed ID: 25875093
[TBL] [Abstract][Full Text] [Related]
14. AGR2, a mucinous ovarian cancer marker, promotes cell proliferation and migration.
Park K; Chung YJ; So H; Kim K; Park J; Oh M; Jo M; Choi K; Lee EJ; Choi YL; Song SY; Bae DS; Kim BG; Lee JH
Exp Mol Med; 2011 Feb; 43(2):91-100. PubMed ID: 21200134
[TBL] [Abstract][Full Text] [Related]
15. Development of an ELISA to detect the secreted prostate cancer biomarker AGR2 in voided urine.
Wayner EA; Quek SI; Ahmad R; Ho ME; Loprieno MA; Zhou Y; Ellis WJ; True LD; Liu AY
Prostate; 2012 Jun; 72(9):1023-34. PubMed ID: 22072305
[TBL] [Abstract][Full Text] [Related]
16. Chromogranin A as serum marker of pituitary adenomas.
Gussi IL; Young J; Baudin E; Bidart JM; Chanson P
Clin Endocrinol (Oxf); 2003 Nov; 59(5):644-8. PubMed ID: 14616890
[TBL] [Abstract][Full Text] [Related]
17. Correlation of AGR2 expression with the incidence of metastasis in luminal breast cancer.
Kereh DS; Pieter J; Hamdani W; Haryasena H; Sampepajung D; Prihantono P
Breast Dis; 2021; 40(S1):S103-S107. PubMed ID: 34092584
[TBL] [Abstract][Full Text] [Related]
18. Plasma matrix metalloproteinase 9 as an early surrogate biomarker of advanced colorectal neoplasia.
Gimeno-García AZ; Triñanes J; Quintero E; Salido E; Nicolás-Pérez D; Adrián-de-Ganzo Z; Alarcón-Fernández O; Abrante B; Romero R; Carrillo M; Ramos L; Alonso I; Ortega J; Jiménez A
Gastroenterol Hepatol; 2016; 39(7):433-41. PubMed ID: 26601990
[TBL] [Abstract][Full Text] [Related]
19. Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2.
Ho ME; Quek SI; True LD; Seiler R; Fleischmann A; Bagryanova L; Kim SR; Chia D; Goodglick L; Shimizu Y; Rosser CJ; Gao Y; Liu AY
Oncotarget; 2016 Mar; 7(13):15747-56. PubMed ID: 26894971
[TBL] [Abstract][Full Text] [Related]
20. Circulating Levels of Adipocytokines as Potential Biomarkers for Early Detection of Colorectal Carcinoma in Egyptian Patients.
Zekri AR; Bakr YM; Ezzat MM; Zakaria MS; Elbaz TM
Asian Pac J Cancer Prev; 2015; 16(16):6923-8. PubMed ID: 26514469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
